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Introduction
The quality-of-life associate with a health state can be quantitatively measured using utility analysis. [1] [2] [3] [4] [5] [6] [7] By convention, utilities range between anchors of 0.0 and 1.0. A utility of 0.0 correlates with death while a utility of 1.0 indicates the quality-of-life associated with normal health (vision) permanently. On this spectrum, a disease associated with poor quality-of-life is associated with a utility closer to 0.0, while a disease associated with good quality-of-life is associated with a utility closer to 1.0.
Comorbidities are secondary health problems which accompany a primary disease of interest. 6 Comorbidities are very prevalent in the middle-aged to older adult population. 8, 9 Among the 1,356 people between the ages of 43 and 84 interviewed in the Beaver Dam Health Outcomes Study, 61.4% had at least one comorbidity. 10 on 27 April 2008 bjo.bmj.com Downloaded from Given the prevalence of comorbidities, the influence of these secondary health problems upon utilities is of considerable interest and raises a number of important questions. For example, how do comorbid illnesses affect the utility (quality-of-life) associated with a specific health state? And if they do, how does this influence the overall value conferred by select healthcare interventions? 6 For example, does cataract surgery confer as much value (benefit) in a person with systemic peripheral neuropathy and renal failure as in someone with the same degree of cataract but in otherwise good systemic health?
Furthermore, it has been the impression of the authors that the overall quality-oflife of patients with serious ocular disease is often determined primarily by their ocular condition. The answer to this question could well allow ophthalmologists to better appreciate the gravity and quality-of-life diminution associated with the diseases they treat.
There is currently no universally accepted method of mathematically combining single disease utilities into a number that represents the quality-of-life associated with a patient's overall health state. 10 The Health Utilities Index classification system is probably the closest; it uses a formula which subtracts disutilities associated with adverse symptoms/signs from the utility of 1.0 associated with normal health. 11 The magnitude of this effect is determined by the number of symptoms/signs and symptom/sign severity associated with a single disease or health state (one or more diseases).
A system in which comorbidities further diminish the quality-of-life associated with a primary health state could theoretically cause an intervention in a person with comorbidities to confer less value (improvement in quality-of-life and/or length-of-life) 6 than in a person with the same primary disease but who is in otherwise good health. To explore this issue, we undertook the study herein to evaluate the effect of comorbidities upon patient, health-related quality-of-life.
Material and Methods
Participants in the study included consecutive adult patients drawn from a vitreoretinal ophthalmic practice. Eligibility for the study required the presence of more than one disease and the absence of Alzheimer's Disease or other forms of dementia. Permission was obtained from each patient who participated and the study was approved by the Wills Eye Hospital Institutional Review Board. Those participants who agreed to enter the study but were unable or unwilling to answer the study questions were excluded from the results.
After an ophthalmologic examination, an interviewer (FJR) asked each participant a series of time tradeoff utility analysis questions appropriate to his or her particular health conditions. The study used 19 different utility assessment forms specific to individual conditions. These included assessments for cardiac, dermatology, diabetic, ear/nose/throat, endocrine, gastroenterology, gynecology, kidney, hematology, hypertension, neurology, oncology, orthopedic, peripheral vascular, pulmonary, rheumatology, urology, and visual conditions. The forms and methodology have been described and validated in previous publications. [6] [7] [8] [9] [12] [13] [14] [15] [16] The ocular conditions present in the study are shown in Table 1 .
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The ocular diseases present included diabetic retinopathy (43%), macular degeneration (30%), lattice degeneration/retinal tear (14%), retinal vascular obstruction (5%), uveitis, macular edema, macular pucker (5%) and vascular tumors (1%) and central serous chorioretinopathy, radiation retinopathy, Coats' disease and trauma in one patient each.
Among the 170 participants, the Snellen visual acuity in the better-seeing eye ranged from 20/20 to light perception. The mean Snellen decimal vision in the betterseeing eye was 0.49, or approximately 20/20, and the median vision was 20/40. The standard deviation from the mean was 0.29 and the 95% confidence interval ranged from Snellen vision of 0.45-0.54.
Utility Analysis
The time tradeoff utility analysis questions were asked in a similar fashion for each of the different health conditions. Participants were first asked, "How long do you expect to live." Each was then asked, "What is the maximum amount of your estimated remaining time of life, if any, you would be willing to theoretically trade in return for an intervention which immediately cures your health problem permanently?" The time tradeoff utility value for each health condition was calculated using the following formula: Utility = 1.0 -(proportion of time traded). For example, if an individual expected to live another 20 years and was willing to trade three years in order to be permanently cured of diabetes mellitus, the associated utility value was 0.85, or [1.0-(3/20)].
All participants in the study underwent time tradeoff utility analysis questions for ophthalmic conditions. Using the anchors of death (utility = 0.00) and normal bilateral vision permanently (20/20 or better bilaterally, which is associated with a utility of 1.00), the time tradeoff utility associated with ocular diseases was calculated in the same manner as described above. [6] [7] [8] [9] [14] [15] [16] [17] [18] After answering time tradeoff utility analysis questions concerning individual health conditions, participants were asked, "What is the maximum amount of your estimated remaining time of life, if any, you would be willing to theoretically trade in return for interventions which immediately and permanently cure all of your health problems? In essence, this question asked how much time a participant was willing to trade to eliminate a primary disease along with all comorbidities. For the purpose of this study, the primary disease was defined as the health condition perceived by the participant to have the most adverse (or least desirable) effect upon his/her quality-of-life. The primary disease was thus associated with the lowest utility value reported for a single disease. Other health conditions accompanying the primary disease were considered to be comorbidities.
The number of disease-specific assessment forms completed by each participant was arbitrarily limited at five due to patient fatigue. In instances requiring the selection of particular health conditions and the exclusion of others, the screening researcher (GCB) selected the diseases which the participants believed most severely affected their qualityof-life.
Statistical Analyses
Sample size. A sample of 170 participants was necessary to give a 90% power of detecting an 8% difference in utility between the two utility groups: 1. the mean utility associated with the primary disease and 2) the mean utility associated with the primary disease and comorbidities grouped together. For an 85% power to demonstrate a 10% difference in mean utility between the two groups, a sample of 95 participants was necessary. Utility standard deviation data from previous reports were used in calculating the sample size with Sample Power 2 (SPSS, Chicago, Ill).
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Sample analysis. Means and standard deviations were determined for the: 1) primary and 2) grouped utilities and a two-tailed, paired t-test was performed to compare the means of the two. An unpaired t-test was employed to assess the continuous variables of age and level of education, while the categorical variables of gender and ethnicity were analyzed using a 
Results
A total of 181 patients participated in the study. Of this number, 11 (6.1%) were unable or unwilling to answer the proposed questions once they were administered. These participants were excluded from the results.
Within the remaining 170 participants, 104 (61%) were women and 66 (39%) were men. One hundred and fifty Caucasian (88%) and 20 non-Caucasian (12%) participants comprised the sample. The mean age was 68.6 years [standard deviation (SD) = 12.5 years], with a median of 71 years. The average number of educational years after kindergarten was 14.3 (SD = 3.1) with a median value of 14 years. Participants had an average of 1.8 ± 0.7 comorbidities in addition to their primary disease. The median number of comorbidities was two. The primary ocular conditions responsible for ophthalmologic referral among the 170 participants who completed the study are shown in Table 1 . Among the 170 participants, 96 (57%) were willing to trade time for the cure of at least one health problem. Forty two (25%) of the 170 participants were willing to trade time be cured of two or more health conditions. Between the groups of participants willing and unwilling to trade time, no significant difference was noted for any of the clinical parameters (Table 3) . 
Utility Analysis
The mean lowest utility reported by participants for a single disease and the mean utility associated with the combination of all diseases are presented in Table 4 . For the total cohort of 170 participants, there was no significant difference between the mean utility reported for the primary health condition and the mean utility associated with the combination grouping of all health conditions (p=0.56). The mean lowest utility reported for a single disease was 0.82 ± 0.22 and the mean utility value associated with eliminating all studied diseases was 0.80 ± 0.24. Among the 96 (56% of total) participants who traded time of remaining life to eliminate at least one health problem, there was also no significant difference between the mean primary disease utility and the mean utility associated with being rid of all discussed health problems (primary disease and comorbidities) (p=0.40). The mean lowest utility reported in this subset for the primary disease was 0.68 ± 0.20 and the mean utility associated with eliminating all studied diseases was 0.65 ± 0.22 (Table 4) .
Within the subgroup of 96 participants willing to trade time, the lowest utilities were associated with vision in 56 (58%), Visual acuity in this group ranged from 20/20 to hand motions in the better-seeing eye, with a mean decimal vision of 0.62, or just less than 20/30, and a mean associated utility of 0.84.
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Discussion
This study shows that the quality-of-life associated with a specific health state is dependent primarily upon the single disease that most adversely affects an individual's quality-of-life. The total group of participants had the same mean utility when queried about the single disease that most unfavorably affected their quality-of-life (primary disease) compared to when queried about their grouped diseases (primary disease and comorbidities). In the participant cohort comprised of those willing to trade time, there was also no significant difference between the primary disease utility mean and the grouped disease utility mean.
Those participants who were willing to trade time and those who were unwilling to trade time demonstrated a similar composition in terms of age, gender, ethnicity, and education. This is not surprising, since utilities have previously been shown to be independent of age, gender, level of education and ethnicity. [5] [6] [7] [8] [9] [12] [13] [14] [15] [16] [17] [18] Among the patients who traded time in the current study, the lowest utility was the visual utility in 58% of cases. In these instances, the patients' quality-of-life was determined primarily by their visual disability, even when other diseases were present. It has been previously demonstrated that systemic comorbidities associated with ocular diseases do not affect ocular utilities 8 , and also that the level of vision rather than the underlying ocular disease, accounts for visual utilities 7 . Nonetheless, we are unaware of the demonstration that the most severe disease, ocular or systemic, rather than a combination of diseases, most often determines overall quality-of-life.
The study is admittedly biased toward an ophthalmic cohort with debilitating ocular diseases and should be repeated in other populations. Nonetheless, the fact that it is ophthalmologic conditions which are responsible for the overall quality-of-life diminution in the majority of this cohort emphasizes the great importance of vision to those with serious ocular diseases. The ophthalmologist's therapeutic message should therefore be carefully crafted, since it has a considerable effect upon a patient's overall quality-of-life.
In some instances, such as diabetes mellitus, a specific adverse condition which occurred secondary to the disease, such as diabetic neuropathy or retinopathy, was associated by a patient with the lowest utility, rather than the diabetes itself. In this situation, whichever of either the diabetes or end-organ disease manifestation of the diabetes, perceived by the patient as the most disabling problem was selected at face value. It was the intent of the authors to assess what each patient believed to be their greatest threat to their quality-of-life, whether a general metabolic disorder such as diabetes mellitus, or one of its end-organ manifestations such as neuropathy or retinopathy. While this can lead to some confusion, diseases are most often grouped clinically according to end-organ effects. 19 An absent or negligible effect of comorbidities upon quality-of-life clashes with the underlying philosophy inherent in some health-related quality-of-life instruments. For example, the Health Utilities Index and the EuroQol 5-D both have mechanisms which allow comorbidities to exert a negative influence upon the overall utility associated with a specific disease. 6, 11 These quality-of-life instruments account for this negative impact through mathematical formulas which reflect the number and severity of the comorbidities involved by subtracting utility points from 1.0 for each symptom/sign. For example, the overall utility of a person with: 1) severe visual loss from cataracts, 2) moderate pain from osteoarthritis of the hip and 3) moderate anxiety would be calculated by subtracting the sum of the disutilities for each from 1.0. Thus, the presence of more comorbidities can further diminish the quality-of-life associated with a primary disease such as severe cataract.
Other researchers 20, 21 have suggested the utility associated with a specific disease should be influenced by the overall health utility of a cohort. In such instances, the conferred value and cost-effectiveness of an intervention are more favorable in otherwise healthy patient cohorts than in patient cohorts with comorbidities. In theory, this could lead to greater healthcare resource allocation to patients who have no or less comorbidities, an approach we find unacceptable. In the U.S., this form of discrimination also runs counter to the Americans with Disabilities Act of 1990 22 , which prevents federal agencies such as the Centers for Medicare and Medicaid Services from denying equal access of goods and services to disabled members of society.
Besides a bias in more highly valuing interventions in the healthiest patients, the inclusion of comorbidities in cost-utility analysis provides an overwhelming task to researchers. According to the International Classification of Diseases, Ninth Revision 19 , over 4,000 disease diagnoses are currently listed. This means an overwhelming 4,000! (factorial) possible quality-of-life health state variants. To establish the conferred value and cost-utility associated with interventions for such a staggering number of combinations is an impossible undertaking. The elimination of comorbidities from most quality-of-life calculations allows for a more realistic hope of developing a useful costutility database. This type of database would be a significant advance in allowing a comparison of the conferred value and cost-effectiveness of most healthcare interventions. 5, 6 As with any report, weaknesses are present in the current study. The comorbidities tested did not affect participants to the same degree of severity and were not represented equally. Nonetheless, comparing the severity of one comorbidity with another in a different organ system is in itself very difficult. Hypertension and diabetes appeared often, while utilities in dermatology, hematology, and gynecology appeared only once, and depression was not evaluated. Since the participants were recruited from a vitreoretinal ophthalmic practice, all participants possessed ocular disease, creating bias toward an ophthalmic population. It is also possible that some of the conclusions might be different if the same patient were tested in a neutral setting, rather than immediately after an ophthalmologic visit. Not all of the comorbidities were examined in some cases, since studies were conducted on no more than five concomitant diseases in a single participant due to the potential for participant fatigue. Additionally, the existence of a smaller significant utility difference than the 8% difference the study was powered to detect is a possibility.
The influence of specific comorbidities on utility values should also be examined in greater detail, for the effect may not always be non-existent or negligible in select cases. Ocular utility values have been previously shown to be independent of systemic comorbidities 8 , but a study of diabetic patients demonstrated that the comorbidity of depression further decreased quality-of-life below the level seen with diabetes mellitus alone 9 . Additional research in this area should be performed to determine whether there are specific situations in which comorbidities must be considered.
In summary, an individual's overall quality-of-life is primarily determined by the single disease which the individual perceives as most severely affecting his/her qualityof-life. Secondary diseases, or comorbidities, appear to play a lesser or negligible role in altering quality-of-life calculations. The quality-of-life associated with the primary disease of an individual is the same as the quality-of-life determined when considering all of the diseases which affect that individual. The understanding of this phenomenon allows physicians to better recognize which factors have the greatest influence in determining a patient's quality-of-life, and thereby theoretically maximize the value conferred by medical interventions.
